Administration of HDACIs mitigates synuclein toxicity by decreasing histone deacetylase activity and increasing histone H3 acetylation, demonstrating their neuroprotective potential in PD (Meyer 2000; Kontopoulos et al. 2006). The gene discussed is SNCA; the disease is Parkinson disease.